ArticleMateria socio-medica2025
The Diagnostic Significance of the Tumor Marker CYFRA 21-1 in Patients with Laryngeal Carcinoma.
Article in Materia socio-medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal squamous cell carcinoma (LSC) is the leading malignant tumour of the head and neck. Establishing new biomarkers is extremely important because they can be important for early diagnosis and prognosis of LSC. Objective: The aim of this study was to establish the significance of cytokeratin fragment antigen 21-1 (CYFRA 21-1) in the early diagnosis and prognosis of LSC. Methods: This was prospective research involving 35 patients of both sexes with pathohistologically confirmed LSC, who were treated in the period from 2022 to 2024. The control group consisted of 30 patients who underwent surgery for other non-malignant diseases and who had a normal indirect laryngoscopy findings. The levels of CYFRA 21-1 were determined for three time periods: preoperative, four weeks after surgery, and three months after radiotherapy or concomitant chemoradiotherapy. For the statistical analysis of data we used descriptive statistics methods, the Student T-test and the χ2 test to calculate the significance of the tested differences, where differences on the level of p<0.05 were considered to be statistically significant. Results: Statistically significantly higher mean serum levels of CYFRA 21-1 were found preoperatively in the experimental group in comparison with the control group (p<0.001). Statistically significant lower levels of CYFRA 21-1 were found four weeks after surgery in the experimental group in comparison with preoperative levels (p=0.004). A statistically significant decrease in serum levels of CYFRA 21-1 was also found three months after radiotherapy or concomitant chemoradiotherapy in comparison with the preoperative levels (p=0.001). The serum levels of CYFRA 21-1 were statistically significantly higher preoperatively in patients with stage III/IV of the disease in comparison with stage I/II (p<0.001). Conclusion: Increased levels of CYFRA 21-1 are a significant indication of the presence of LSC, especially in patients with advanced stages of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.